Tai Li Sheng Wu Yi Yao

Taili Bio is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, focused on the discovery and development of innovative small molecule drugs for oncology and immunology. The company leverages its proprietary drug discovery platform to target high-value pathways such as CDK9 and BTK, aiming to address unmet medical needs in hematological malignancies and solid tumors. Taili Bio's lead programs include TL-010, a highly selective CDK9 inhibitor, and TL-011, a next-generation BTK inhibitor. The company is led by a team of industry veterans with extensive experience in global drug development and has secured significant venture capital funding to advance its pipeline.